Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:09:56 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:ACOR from 2023-05-04 to 2024-05-03 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-15 17:03U:ACORNews ReleaseAcorda Therapeutics Announces Delisting from Nasdaq
2024-04-03 17:30U:ACORNews ReleaseAcorda Therapeutics Announces Nasdaq Delisting Notification
2024-04-01 18:35U:ACORNews ReleaseAcorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
2024-04-01 16:01U:ACORNews ReleaseAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
2024-03-25 16:01U:ACORNews ReleaseAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
2024-01-11 08:01U:ACORNews ReleaseAcorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA ‚ ® by January 2025
2023-11-13 16:01U:ACORNews ReleaseAcorda Therapeutics Reports Third Quarter 2023 Financial Results
2023-11-06 16:01U:ACORNews ReleaseAcorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
2023-11-06 08:00U:ACORNews ReleaseAcorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA ‚ ®
2023-08-08 16:01U:ACORNews ReleaseAcorda Therapeutics Reports Second Quarter 2023 Financial Results
2023-08-02 08:00U:ACORNews ReleaseAcorda Therapeutics Announces Launch of New INBRIJA ‚ ® Campaign: ¢ € œFor The Fighters ¢ „ ¢ ¢ € 
2023-08-01 08:00U:ACORNews ReleaseAcorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
2023-06-28 17:08U:ACORNews ReleaseTom Burns Elected to the Acorda Therapeutics Board of Directors
2023-06-26 08:00U:ACORNews ReleaseAcorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
2023-06-02 16:01U:ACORNews ReleaseAcorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
2023-05-31 16:01U:ACORNews ReleaseAcorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
2023-05-30 08:00U:ACORNews ReleaseAcorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
2023-05-11 16:01U:ACORNews ReleaseAcorda Therapeutics Reports First Quarter 2023 Financial Results
2023-05-10 07:00U:ACORNews ReleaseAcorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
2023-05-08 07:00U:ACORNews ReleaseAcorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA ‚ ® in China
2023-05-04 09:41U:ACORNews ReleaseAcorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023